TI
YMAB

Trexquant Investment’s Y-mAbs Therapeutics YMAB Stock Holding History

Trexquant Investment’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,616
Closed -$195K – 1838
2023
Q4 		$195K Sell
28,616
-47,969
-63% -$277K ﹤0.01% 1342
2023
Q3 		$417K Buy
76,585
+61,785
+417% +$360K 0.01% 1093
2023
Q2 		$100K Buy
+14,800
New +$111K ﹤0.01% 1372
2022
Q4 		– Sell
-15,912
Closed -$229K – 1792
2022
Q3 		$229K Buy
+15,912
New +$264K 0.01% 1134
2021
Q3 		– Sell
-8,690
Closed -$294K – 1544
2021
Q2 		$294K Sell
8,690
-852
-9% -$27.3K 0.02% 722
2021
Q1 		$289K Buy
+9,542
New +$391K 0.03% 772

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's YMAB Position: Q1 2024 in Review

Trexquant Investment sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 28,616 shares — an estimated $195K sold.

Trexquant Investment first reported a position in YMAB in Q1 2021 and held it in 6 quarters. The position peaked at $417K in Q3 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • Trexquant Investment reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Trexquant Investment sold 28,616 Y-mAbs Therapeutics shares in Q1 2024, an estimated $195K.
  • Trexquant Investment first reported a position in Y-mAbs Therapeutics in Q1 2021 and held it in 6 quarters.
  • Trexquant Investment's Y-mAbs Therapeutics position peaked at $417K in Q3 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Trexquant Investment's 13F filing for Q1 2024, filed 14 May 2024.